# Study to Assess the Blood Concentrations and Actions of Recombinant Human Parathyroid Hormone (rhPTH [1-84]) When Given Once and Twice Daily to Participants With Hypoparathyroidism

> **NCT02781844** · PHASE1 · COMPLETED · sponsor: **Shire** · enrollment: 34 (actual)

## Conditions studied

- Hypoparathyroidism

## Interventions

- **DRUG:** 25mcg rhPTH(1-84)
- **DRUG:** 50mcg rhPTH(1-84)
- **DRUG:** 100mcg rhPTH(1-84)

## Key facts

- **NCT ID:** NCT02781844
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-03
- **Primary completion:** 2019-03-08
- **Final completion:** 2019-03-08
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2021-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02781844

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02781844, "Study to Assess the Blood Concentrations and Actions of Recombinant Human Parathyroid Hormone (rhPTH [1-84]) When Given Once and Twice Daily to Participants With Hypoparathyroidism". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02781844. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*